Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose

Description: GBI Research, the leading business intelligence provider, has released its latest research, “Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose”, which provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes insights into the seasonal influenza vaccine R&D pipeline and gives profiles of promising vaccines, as well as exploring the competitive landscape through profiles for the top companies. Key trends in terms of M&A and licensing agreements are also analyzed.

GBI Research expects the market to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the 2011–2018 period from $2.9 billion in 2011 to $3.8 billion by 2018, driven by growing awareness, increasing vaccination coverage and rising government support for immunization against seasonal influenza. On the other hand, limited production capacity, high investment and strict regulations may act as barriers to entry.

The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germany's market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.

GBI Research's analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.

Scope

- Data and analysis on the seasonal influenza vaccine market in the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan
- Market forecasts for seasonal influenza vaccines until 2018
- Market data on geographical landscape in terms of country, vaccination coverage, public and private contribution to the total number of doses, vaccine price and market size
- Key drivers and restraints that have had a significant impact on the market
- Regulatory landscape, including the approval process and an overview of the regulatory authorities in the top seven countries
- Competitive landscape of the seasonal influenza vaccine market in the top seven countries including top companies' profiles, namely Sanofi, Johnson & Johnson, GlaxoSmithKline Biologicals, Novartis Vaccines and AstraZeneca
- Key M&A activities and licensing agreements that have taken place between 2009 and mid-2012
Reasons to buy

- Build effective strategies to launch pipeline products by identifying potential geographies
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
- Develop key strategic initiatives by studying top competitors' key strategies
- Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms able to produce safer and more efficacious first-in-class vaccines

Contents:

1.1 List of Tables
1.2 List of Figures

2 Seasonal Influenza Vaccines Market in Top Seven Countries - Introduction

3 Seasonal Influenza Vaccine Market in Top Seven Countries - Market Overview
3.1 Production Cycle for Seasonal Influenza Vaccines
3.2 Seasonal Influenza Vaccine Market in Top Seven Countries
3.2.1 Vaccination Pattern
3.2.2 Total Revenue
3.3 Drivers and Restraints
3.3.1 Drivers
3.3.2 Restraints

4 Seasonal Influenza Vaccine Market in Top Seven Countries - Geographical Landscape
4.1 The US
4.1.1 Vaccination Pattern
4.1.2 Vaccine Cost
4.1.3 Total Revenue
4.2 Drivers and Restraints
4.2.1 Drivers
4.2.2 Barriers
4.3 The UK
4.3.1 Vaccination Pattern
4.3.2 Vaccine Cost
4.3.3 Total Revenue
4.4 Drivers and Restraints
4.4.1 Drivers
4.4.2 Restraint
4.5 France
4.5.1 Vaccination Pattern
4.5.2 Vaccine Cost
4.5.3 Total Revenue
4.6 Drivers and Restraints
4.6.1 Drivers
4.6.2 Restraints
4.7 Italy
4.7.1 Vaccination Pattern
4.7.2 Vaccine Cost
4.7.3 Total Revenue
4.8 Drivers and Restraints
4.8.1 Drivers
4.8.2 Restraints
4.9 Spain
4.9.1 Vaccination Pattern
4.9.2 Vaccine Cost
4.9.3 Total Revenue
4.10 Drivers and Restraints
4.10.1 Drivers
4.10.2 Restraints
4.11 Germany
4.11.1 Vaccination Pattern
4.11.2 Vaccine Cost
4.11.3 Total Revenue
4.12 Drivers and Restraints
4.12.1 Drivers
4.12.2 Restraints
4.13 Japan
4.13.1 Vaccination Pattern
4.13.2 Vaccine Cost
4.13.3 Total Revenue
4.14 Drivers and Restraints
4.14.1 Drivers
4.14.2 Restraints

5 Seasonal Influenza Vaccine Market in Top Seven Countries - Regulatory Landscape
5.1 Registration Process and Regulations for Vaccines in the US
5.2 Registration Process and Regulations for Vaccines in the EU
5.3 Registration Process and Regulations for Vaccines in Japan

6 Seasonal Influenza Vaccine Market in Top Seven Countries - Pipeline Analysis
6.1 Summary
6.2 Research and Development Pipeline by Phase
6.3 Promising Vaccines under Clinical Development
6.3.1 Flu Q-QIV
6.3.2 Optaflu
6.3.3 Fluzone QIV
6.3.4 FluBlok
6.3.5 Q-LAIV Flu Vac

7 Seasonal Influenza Vaccine Market in Top Seven Countries - Competitive Landscape
7.1 Market Share Analysis
7.2 Competitive Profiling
7.2.1 Sanofi Pasteur
7.2.2 GlaxoSmithKline
7.2.3 Novartis Vaccines
7.2.4 AstraZeneca

8 Seasonal Influenza Vaccine Market in Top Seven Countries - Strategic Consolidation
8.1 Overview
8.1.1 Segmentation by Deal Type
8.1.2 Segmentation by Year
8.2 Major Merger and Acquisition Deals, 2009–2012
8.2.1 Intrexon Acquires Neugenesis
8.2.2 Grupo Ferrer Internacional Completes Acquisition of 50% Stake in Alentia Biotech from Laboratorios Farmaceuticos
8.2.3 Nexus Merges with HX Diagnostics
8.2.4 Mymetics Acquires Viroscope Biologicals
8.2.5 Abbott Laboratories Acquires Solvay Pharmaceuticals
8.2.6 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
8.2.7 Johnson & Johnson Acquires Crucell
8.2.8 VBI Vaccines Acquires Epixis
8.2.9 Sanofi Pasteur Acquires Remaining 50% Joint Venture Interest in Sanofi Pasteur-Daiichi Sankyo Vaccines
8.2.10 Segmentation by Geography
8.2.11 Segmentation by Year
8.3 Major Licensing Agreements, 2009–2012
8.3.1 Baxter International Expands its Licensing Agreement with Takeda Pharma
8.3.2 AltraVax Enters into Licensing Agreement with Maxygen
8.3.3 iBio Enters into Licensing Agreement with G-Con
8.3.4 NasVax Extends its Research Agreement with Novartis
8.3.5 Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
8.3.6 Segmentation by Geography
8.3.7 Segmentation by Year
8.4 Major Partnership Deals
8.4.1 Merck Enters into Agreement with CSL Biotherapies
8.4.2 GenVec Enters into an Agreement with SAIC-Frederick
8.4.3 UMN Pharma Enters into Co-Development Agreement with API
8.4.4 Daichi Sankyo Forms Joint Venture with Kitasato Institute Research
8.4.5 Novartis International Enters into an Agreement with Synthetic Genomics Vaccines
8.4.6 PPD Enters into Collaboration Agreement with Southern Research Institute
8.4.7 Segmentation by Geography
8.4.8 Segmentation by Year

9 Seasonal Influenza Vaccine Market in Top Seven Countries - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Secondary Research
9.4.2 Primary Research
9.4.3 Model for Estimation of Seasonal Influenza Vaccine Market
9.5 Geographical Landscape
9.6 Pipeline Analysis
9.7 Competitive Landscape
9.8 Strategic Consolidations
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables

Table 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population ('000), 2011–2018
Table 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 2011–2018
Table 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Overall Vaccination Coverage ('000), 2011–2018
Table 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group ('000), 2011–2018
Table 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Total Number of Doses ('000), 2011–2018
Table 6: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group ('000), 2011–2018
Table 7: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 2011–2018
Table 8: Seasonal Influenza Vaccine Market, The US, Population ('000), 2011–2018
Table 9: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 2011–2018
Table 10: Seasonal Influenza Vaccine Market, The US, Overall Vaccination Coverage ('000), 2011–2018
Table 11: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group ('000), 2011–2018
Table 12: Seasonal Influenza Vaccine Market, The US, Total Number of Doses ('000), 2011–2018
Table 13: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group ('000), 2011–2018
Table 14: Seasonal Influenza Vaccine Market, The US, Number of Doses by Sector ('000), 2011–2018
Table 15: Seasonal Influenza Vaccine Market, The US, Vaccine Cost ($), 2011–2018
Table 16: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 2011–2018
Table 17: Seasonal Influenza Vaccine Market, The UK, Population ('000), 2011–2018
Table 18: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group (%), 2011–2018
Table 19: Seasonal Influenza Vaccine Market, The UK, Overall Vaccination Coverage ('000), 2011–2018
Table 20: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group ('000), 2011–2018
Table 21: Seasonal Influenza Vaccine Market, The UK, Total Number of Doses ('000), 2011–2018
Table 22: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group ('000), 2011–2018
Table 23: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Sector ('000), 2011–2018
Table 24: Seasonal Influenza Vaccine Market, The UK, Vaccine Cost ($), 2011–2018
Table 25: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 2011–2018
Table 26: Seasonal Influenza Vaccine Market, France, Population ('000), 2011–2018
Table 27: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 2011–2018
Table 28: Seasonal Influenza Vaccine Market, France, Overall Vaccination Coverage ('000), 2011–2018
Table 29: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group ('000), 2011–2018
Table 30: Seasonal Influenza Vaccine Market, France, Total Number of Doses ('000), 2011–2018
Table 31: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group ('000), 2011–2018
Table 32: Seasonal Influenza Vaccine Market, France, Number of Doses by Sector Contribution ('000), 2011–2018
Table 33: Seasonal Influenza Vaccine Market, France, Vaccine Cost ($), 2011–2018
Table 34: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 2011–2018
Table 35: Seasonal Influenza Vaccine Market, Italy, Population ('000), 2011–2018
Table 36: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 2011–2018
Table 37: Seasonal Influenza Vaccine Market, Italy, Overall Vaccination Coverage ('000), 2011–2018
Table 38: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group ('000), 2011–2018
Table 39: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Sector Contribution ('000), 2011–2018
Table 40: Seasonal Influenza Vaccine Market, Italy, Vaccine Cost ($), 2011–2018
Table 41: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 2011–2018
Table 42: Seasonal Influenza Vaccine Market, Spain, Population ('000), 2011–2018
Table 43: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 2011–2018
Table 44: Seasonal Influenza Vaccine Market, Spain, Overall Vaccination Coverage ('000), 2011–2018
Table 45: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group ('000), 2011–2018
Table 46: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Sector Contribution ('000), 2011–2018
Table 47: Seasonal Influenza Vaccine Market, Spain, Vaccine Cost ($), 2011–2018
Table 48: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 2011–2018
Table 49: Seasonal Influenza Vaccine Market, Germany, Population ('000), 2011–2018
Table 50: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 2011–2018
Table 51: Seasonal Influenza Vaccine Market, Germany, Overall Vaccination Coverage ('000), 2011–2018
Table 52: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group ('000), 2011–2018
Table 53: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Sector Contribution ('000), 2011–2018
Table 54: Seasonal Influenza Vaccine Market, Germany, Vaccine Cost ($), 2011–2018
Table 55: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 2011–2018
Table 56: Seasonal Influenza Vaccine Market, Japan, Population ('000), 2011–2018
Table 57: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 2011–2018
Table 58: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage ('000), 2011–2018
Table 59: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group ('000), 2011–2018
Table 60: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Sector Contribution ('000), 2011–2018
Table 61: Seasonal Influenza Vaccine Market, Japan, Vaccine Cost ($), 2011–2018
Table 62: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 2011–2018
Table 63: Seasonal Influenza Vaccine Market, Promising Vaccines by Phase of Development and Company, 2012

1.2 List of Figures

Figure 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population ('000), 2011–2018
Figure 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 2011–2018
Figure 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group ('000), 2011–2018
Figure 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 2011–2018
Figure 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Drivers and Restraints
Figure 6: Seasonal Influenza Vaccine Market, The US, Population ('000), 2011–2018
Figure 7: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 2011–2018
Figure 8: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group ('000), 2011–2018
Figure 9: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 2011–2018
Figure 10: Seasonal Influenza Vaccine Market, The US, Drivers and Restraints
Figure 11: Seasonal Influenza Vaccine Market, The UK, Population ('000), 2011–2018
Figure 12: Seasonal Influenza Vaccine Market, The UK, Vaccinated Coverage by Age Group (%), 2011–2018
Figure 13: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group ('000), 2011–2018
Figure 14: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 2011–2018
Figure 15: Seasonal Influenza Vaccine Market, The UK, Drivers and Restraints
Figure 16: Seasonal Influenza Vaccine Market, France, Population ('000), 2011–2018
Figure 17: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 2011–2018
Figure 18: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group ('000), 2011–2018
Figure 19: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 2011–2018
Figure 20: Seasonal Influenza Vaccine Market, France, Drivers and Restraints
Figure 21: Seasonal Influenza Vaccine Market, Italy, Population ('000), 2011–2018
Figure 22: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 2011–2018
Figure 23: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group ('000), 2011–2018
Figure 24: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 2011–2018
Figure 25: Seasonal Influenza Vaccine Market, Italy, Drivers and Restraints
Figure 26: Seasonal Influenza Vaccine Market, Spain, Population ('000), 2011–2018
Figure 27: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 2011–2018
Figure 28: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group ('000), 2011–2018
Figure 29: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 2011–2018
Figure 30: Seasonal Influenza Vaccine Market, Spain, Drivers and Restraints
Figure 31: Seasonal Influenza Vaccine Market, Germany, Population ('000), 2011–2018
Figure 32: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 2011–2018
Figure 33: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group ('000), 2011–2018
Figure 34: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 2011–2018
Figure 35: Seasonal Influenza Vaccine Market, Germany, Drivers and Restraints
Figure 36: Seasonal Influenza Vaccine Market, Japan, Population ('000), 2011–2018
Figure 37: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 2011–2018
Figure 38: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group ('000), 2011–2018
Figure 39: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 2011–2018
Figure 40: Seasonal Influenza Vaccine Market, Japan, Drivers and Restraints
Figure 41: Seasonal Influenza Vaccine Market, Regulatory Authorities, The US, 2012
Figure 42: Seasonal Influenza Vaccine Market, Drug Approval Process, The US, 2012
Figure 43: Seasonal Influenza Vaccine Market, Regulatory Authorities, EU, 2012
Figure 44: Seasonal Influenza Vaccine Market, Approval Process, EU, 2012
Figure 45: Seasonal Influenza Vaccine Market, Regulatory Authorities, Japan, 2012
Figure 46: Seasonal Influenza Vaccine Market, Drug Approval Process, Japan, 2012
Figure 47: Seasonal Influenza Vaccine Market, Top Seven Countries, R&D Pipeline by Phase (%), 2012
Figure 48: Seasonal Influenza Vaccine Market, Top Seven Countries, Market Share (%), 2011
Figure 49: Seasonal Influenza Vaccine Market, Top Seven Countries, Sanofi, SWOT Analysis
Figure 50: Seasonal Influenza Vaccine Market, Top Seven Countries, GSK, SWOT Analysis
Figure 51: Seasonal Influenza Vaccine Market, Top Seven Countries, Novartis, SWOT Analysis
Figure 52: Seasonal Influenza Vaccine Market, Top Seven Countries, AstraZeneca, SWOT Analysis
Figure 53: Seasonal Influenza Vaccine Market, Top Seven Countries, Deals by Type, 2009–2012
Figure 54: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Deals by Year, 2009–2012
Figure 55: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Geography, 2009–2012
Figure 56: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Year, 2009–2012
Figure 57: Seasonal Influenza Vaccine Market, Top Seven Countries, Licensing Agreements by Geography, 2009–2012
Figure 58: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Licensing Agreements by Year, 2009–2012
Figure 59: Seasonal Influenza Vaccine Market, Top Seven Countries, Partnership Deals by Geography, 2009–2012
Figure 60: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Partnership Deals by Year, 2009–2012
Figure 61: GBI Research Market Forecasting Model, Estimation of Market for a Country, 2010

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2293282/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose
Web Address: http://www.researchandmarkets.com/reports/2293282/
Office Code: SC615RZO

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World